Results 281 to 290 of about 1,443,667 (357)

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. [PDF]

J Transl Med
Li Z, Zhang F, Jin X, Zhuang J.
europepmc   +1 more source

Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis. [PDF]

J Hematol Oncol
Wu Y, Yan Y, Guo Y, Niu M, Zhou B, Zhang J, Zhou P, Chu Q, Mei Q, Yi M, Wu K.   +10 more
europepmc   +1 more source

A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro. [PDF]

Sci Rep
Petersen I, Morrison JI, Petrovic A, Babic N, Metzendorf NG, Godec A, de la Rosa A, Rofo F, Bondza S, Buijs J, Ranjbarian F, Hofer A, Sehlin D, Hultqvist G.   +13 more
europepmc   +1 more source

Sequence and Configuration of a Novel Bispecific Antibody Format Impacts Its Production Using Chinese Hamster Ovary (CHO) Cells. [PDF]

Biotechnol Bioeng
Hussain H, Ozanne AMS, Patel T, Vito D, Ellis M, Hinchliffe M, Humphreys DP, Stephens PE, Sweeney B, White J, Dickson AJ, Smales CM.   +11 more
europepmc   +1 more source

Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. [PDF]

J Immunother Cancer
Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S, Liu D, Wang L.   +7 more
europepmc   +1 more source

Engineering and physicochemical characterization of a novel, stable, symmetric bispecific antibody with dual target-binding using a common light chain. [PDF]

Protein Sci
Saito S, Nakayama M, Yamazaki K, Miyamoto Y, Hiraishi K, Tomioka D, Takagi-Maeda S, Usami K, Takahashi N, Nara S, Imai E.   +10 more
europepmc   +1 more source

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial. [PDF]

Nat Commun
Xu D, Wang H, Bao Q, Jin K, Liu M, Liu W, Yan X, Wang L, Zhang Y, Wang G, Ma Y, Ma Z, Zhang C, Tang J, Wang S, Pang J, Xu T, Wang K, Xing B.   +18 more
europepmc   +1 more source

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects. [PDF]

J Immunother Cancer
Capello M, Sette A, Plantinga T, Thalhauser CJ, Spires VM, Nürmberger KB, Blum JM, Higgs BW, Garrido Castro P, Yu C, Costa Sa C, Fellermeier-Kopf S, Burm SM, Strumane K, Toker A, Imle A, de Andrade Pereira B, Muik A, Ahmadi T, Türeci Ö, Fereshteh M, Sahin U, Jure-Kunkel M, Pencheva N.   +23 more
europepmc   +1 more source

Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer. [PDF]

Clin Transl Sci
Zhu M, Madia P, Crawford A, Brouwer-Visser J, Krueger P, Haber L, Peterman M, Uldrick TS, Miller E, Davis JD, Retter MW.   +10 more
europepmc   +1 more source

Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4. [PDF]

Adv Sci (Weinh)
Liu Z, Chu H, Zhao W, Yang C, Liu T, Shen N, Tang Z.   +6 more
europepmc   +1 more source